In ovo vaccination is usually sold on convenience: one pass, no chick handling, thousands of eggs an hour. That case is easy to make and it is not the interesting one. The question worth answering is narrower. What measurably changes inside the bird when the vaccine goes in on day 18 instead of the morning after hatch, and what does not change at all?
Key takeaways
- Day-old chicks vaccinated in ovo with HVT showed innate and cell-mediated responses comparable to chicks already one to two weeks old.
- Against an early post-hatch challenge with virulent Marek’s disease virus, embryo vaccination at 18 days gave better protection than vaccination at hatch.
- Maternal antibodies do not cancel the method, but they raise the dose needed. Experimental work put the PD50 of cell-associated HVT at 57 plaque-forming units without maternal antibody and 105 with it.
- Cell-associated vaccines live in liquid nitrogen. A thaw at the wrong temperature can destroy titer before the needle ever touches an egg.
What the day 18 injection does to an immune system that is not finished
The embryo at 18 days is not immunologically blank, but it is incomplete. Its defenses rest largely on innate mechanisms and on antibodies transferred from the breeder hen. Introducing herpesvirus of turkeys at that point does something a post-hatch injection cannot: it engages the system while it is still being built.
The measurable output is documented. Work in specific-pathogen-free chickens found that HVT given in ovo at day 18 produced innate and cell-mediated responses comparable to those of chicks one to two weeks of age. One-day-old birds vaccinated in ovo carried higher proportions of CD45+, MHC-I+, CD3+ and CD8+ cells in the spleen than sham-inoculated hatchmates, and an increased share of activated T cells was still evident by four days of age.
That is the mechanism behind the claim. Not a vague head start, but a maturation of cellular immunity brought forward by roughly a week at the point in the bird’s life when field exposure begins.
Earlier is not just more convenient, it protects better
The comparison that matters to a production veterinarian is in ovo against vaccination at hatch, under challenge. Published work on Marek’s disease found that vaccinating 18-day embryos induced better protection against early post-hatch challenge with virulent MDV than vaccinating chicks at hatch, and it did so despite maternally derived antibodies being present.
The window matters because Marek’s exposure in a contaminated house starts at placement. A vaccine that needs several days to establish protection is racing the challenge. Shortening that race by two or three days is the entire clinical argument for the method.
| Criterion | In ovo, day 18 to 19 | Subcutaneous at hatch |
|---|---|---|
| Timing relative to field exposure | Two to three days ahead of placement | Same day as placement |
| Cellular immune status at day old | Elevated splenic T cell populations reported | Response still to be initiated |
| Handling of the chick | None, the bird is not touched | Individual restraint of every chick |
| Main failure mode | Wrong compartment, contamination at the puncture, drifting dose | Missed birds, wrong injection site, operator fatigue |
| Verification of coverage | Indirect, through residue breakout and dose audit | Direct, by sampling birds after the crew |
Maternal antibodies raise the price of entry
Antibody transferred from the breeder hen interferes with vaccine take, and the effect has been quantified. In experimental work on embryo vaccination, the PD50 of cell-associated HVT was 57 plaque-forming units in the absence of maternal antibody and 105 plaque-forming units in its presence. Roughly twice the dose for the same protective effect.
Two things follow. Dose accuracy is not a quality nicety, it is the difference between a protective and a subprotective delivery in a flock carrying high maternal titers. And cell-associated recombinant HVT vaccines hold an advantage here, because they establish latency and reactivate periodically in a long-lived bird, which is how they work through maternal interference rather than around it.
The health benefit is conditional on a cold chain most people underestimate
Cell-associated Marek’s and HVT vaccines, including the vectored products built on them, ship as concentrated suspensions of infected cells in sealed glass ampoules held in liquid nitrogen. These are living cells. They are fragile, and mishandling costs titer silently, with no visible sign at the injector and no alarm in the hatch report.
The published handling parameters are narrow. Manufacturer guidance specifies thawing for 70 to 90 seconds with a water bath held at about 27 °C, and no more than 150 seconds total between thaw and addition to the diluent. Experimental work found that thawing at 20 °C or 40 °C for 45 seconds severely lowered the titer of an HVT and SB-1 vaccine, and that 45 °C for 45 seconds destroyed it completely. Diluent temperature matters in the same way, with the highest recovered titers at 30 °C to 37 °C and the lowest at 5 °C. An ampoule that has been thawed is never refrozen.
This is where an in ovo program is most often quietly undermined. The equipment is audited, the injection is audited, and the two minutes at the water bath, performed by whoever is on shift, are not.
Scale, and what scale does not fix
The method is no longer novel. The first commercial in ovo system was launched in 1992, and industry figures put in ovo use at more than 90% of birds in the United States and around 70% in Brazil, with over 15 billion eggs vaccinated this way each year worldwide. A full-size machine handles up to 70,000 eggs per hour depending on configuration.
None of that throughput improves chick health by itself. A machine applies the same procedure to every egg, correct or incorrect, which is precisely why the execution errors compound at that volume. We have set the four recurring ones out separately, in our review of the common mistakes in in ovo vaccination.
It is also worth being clear about what the method is not. In ovo vaccination protects against the specific pathogens in the products administered. It does not reduce contamination pressure in the hatchery, it does not compensate for poor egg hygiene, and it does not remove the need for post-hatch vaccination where the disease profile calls for it.
Questions we are asked about the method
Does in ovo vaccination reduce hatchability?
Correctly executed, on embryos at the right developmental stage and with clean eggs, it is used at commercial scale precisely because it does not carry a hatchability penalty worth the cost. Losses appear when eggs are injected too early, when they are wrongly positioned so the needle reaches vital organs, or when contamination enters through the puncture. Those are execution problems rather than properties of the method.
Can every poultry vaccine be given in ovo?
No. Only products licensed for embryo administration may be used this way, and the range is narrower than the post-hatch catalogue. Which vaccines, which strains and which schedule apply to a given flock is a veterinary decision based on the disease situation where the birds are going.
Is the method only viable for very large hatcheries?
Not any longer. Alongside full-size equipment, compact machines working at roughly 12,000 to 20,000 eggs per hour have brought the method within reach of smaller operations. The limiting factor is usually the discipline around the vaccine, not the size of the site.
The chick leaves with more than its vaccination status
Early immunity is one input among several. Air quality, temperature and handling in the hatchery shape day-old chick health just as directly.
Read how the hatchery environment affects day-old chick health
Sources: peer-reviewed work on in ovo HVT vaccination and embryo immune maturation, including studies indexed in PubMed on splenic T cell populations after day 18 administration and on maternal antibody effects on HVT PD50; published research on thawing and dilution conditions for cell-bound Marek’s disease vaccines; manufacturer handling instructions for cell-associated HVT products; industry data on in ovo adoption and equipment throughput. Consulted August 2026.
Vaccine selection, strain choice and vaccination schedules are veterinary decisions for the flocks concerned. This article describes the method and its execution, not a protocol to apply.